---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-044293"
form_type: "8-K"
ticker: "CYPH"
cik: "0001509745"
company_name: "CYPHERPUNK TECHNOLOGIES INC."
filed_at: "2023-04-12T23:59:59+00:00"
generated_at: "2026-06-17T03:04:08.464049+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Leap Therapeutics completes Part A enrollment (33 pts) in Phase 2 DeFianCe study of DKN-01 for colorectal cancer

## Summary
- Part A enrolled 33 patients with advanced colorectal cancer; study is randomized, open-label, multicenter.
- Part B is planned as a 130-patient randomized controlled trial; primary endpoint is progression-free survival.
- Initial data from the study expected in mid-2023.
- Secondary endpoints include overall response rate, duration of response, and overall survival.

## SEC filing metadata
- accession: 0001104659-23-044293
- form_type: 8-K
- ticker: CYPH
- cik: 0001509745
- company_name: CYPHERPUNK TECHNOLOGIES INC.
- filed_at: 2023-04-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509745/000110465923044293/0001104659-23-044293-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509745/000110465923044293/tm2312449d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-044293
- JSON: https://secwatch.observer/filing/0001104659-23-044293.json
- Plain text: https://secwatch.observer/filing/0001104659-23-044293.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.